

ENC: [COVAX Facility] Shareholders Council Follow-ups: Info packs (1 of 2)

Flavio Werneck Noce Dos Santos

Enviado: quarta-feira, 11 de novembro de 2020 14:51

Para: Fernanda Martins Torres

Anexos: Shareholders Council - Mee~1.pdf (2 MB) ; 201103 COVAX Facility_Info~1.pdf (5 MB) ; Schedule 2 .docx (48 KB)

De: Yoshinobu Nagamine [ynagamine@gavi.org]

Enviado: quarta-feira, 11 de novembro de 2020 12:41

Para: Flavio Werneck Noce Dos Santos; Indira Meira Gonçalves; Tatiana Silva Estrela; victor.cirne@itamaraty.gov.br; nilo.dytz@itamaraty.gov.br

Cc: COVAX Facility

Assunto: FW: [COVAX Facility] Shareholders Council Follow-ups: Info packs (1 of 2)

Dear Flavio,

Thanks again for the pleasant news of yesterday!

I would like to convey the reminder from the Covax team of the option window which will close on November 16, 2020, as communicated by Gavi's Governance Director Brenda Killen on last Tuesday.

Please do not hesitate to reach out should you have any questions!

Yoshi

From: Brenda Killen <bkillen@gavi.org>

Sent: Tuesday, November 3, 2020 9:31 PM

To: COVAX Facility <covax@Gavi.org>

Subject: [COVAX Facility] Shareholders Council Follow-ups: Info packs (1 of 2)

Dear Shareholders Council members,

Thank you for participating in the first Shareholders Council meeting. We appreciate your time and welcome the opportunity to answer your questions. We will follow up shortly on other topics (e.g., governance), but wanted to immediately reach out regarding two time sensitive topics.

1. Inclusion of mRNA vaccine candidates in COVAX Facility portfolio

As discussed during the meeting, and as per the pre-read document shared last week, we kindly request your guidance on the inclusion of mRNA vaccines in the COVAX Facility portfolio. Specifically, we ask that you share your first choice from the following three options. This information will be used to inform the COVAX Facility's deal-making strategy.

- **Option A:** Inclusion of mRNA vaccines with significant volumes (hundreds of millions of doses in the portfolio)
- **Option B:** Inclusion of mRNA vaccines with small volumes (tens of millions of doses in the portfolio)

- **Option C:** No inclusion of mRNA vaccines in the COVAX Facility portfolio

We kindly request that you use the short form below to reply to this email with your preference by 23:59 CET on 16 November 2020.

Form for responding on topic of mRNA vaccine inclusion

1. **Preferred Option:** [please select one option from the three listed above - Option A, Option B, or Option C]
2. **Your indicative demand for mRNA vaccine doses in 2021 (millions of doses):**
[please enter]
3. **Additional comments:** [please enter]

2. First opt-out window for three vaccine candidates

With the opening of the first opt-out window, we request that you notify the COVAX Facility of whether you would like **to opt-out** of any of the three vaccine candidates presented during the meeting on November 2nd, 2020: (i) AstraZeneca's ChAdOx1-S, (ii) Sanofi / GSK's recombinant protein-based vaccine, and (iii) Pfizer / BioNTech's BNT162.

To inform your decision-making, **please find attached** an information fact-pack with additional technical, clinical, regulatory, and commercial details of the three vaccine candidates.

If you wish to opt-out of purchasing doses of any of these vaccine candidates, please notify the COVAX Facility, using Schedule 2 (see attached "Form of Non-Participation Notice") of the Commitment Agreement. If you decide to opt-out, you will not be issued any potential options to procure doses of the relevant vaccine from the relevant Advance Purchase Commitment. This decision cannot be changed at a later stage.

If you wish to participate in these deals (and receive your share of doses from these three manufacturers, pending successful vaccine development), no further action is required.

We kindly request your input on both topics by **23:59 CET on 16 November 2020**.

Finally, please know that we have confirmed with our legal counsel that you may discuss these materials with other members of your government on an as needed basis per the non-disclosure agreement (NDA) that you signed. We hope that this will allow you to have the right conversations to inform your decisions.

Many thanks,
Brenda Killen

Brenda Killen

Director, Governance

Tel: + 41 22 909 66 80

Mob: + 41 79 554 57 04

Email: bkillen@gavi.org



IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET
